N-Acetyl-Cysteine (NAC)
Extensively StudiedCheap, daily-safe glutathione precursor with massive evidence base — FDA-approved for paracetamol overdose (gold-standard antidote since… | Supplement · Powder
Aliases (8)
▸ Mixing & scoop math Powder
- • Mix into 8-16 oz cold water (or sports drink / protein shake). Most powders dissolve in < 30 sec with a brisk stir.
- • If using a shaker, add liquid first, then powder, then shake — minimizes foam and clumps.
- • Hot water is fine for most amino acids and creatine; avoid for heat-sensitive compounds (NAC degrades above ~60 °C).
- • Drink within 5-10 min of mixing — most powders are stable in solution but taste degrades.
▸ Overview TL;DR
Cheap, daily-safe glutathione precursor with massive evidence base — FDA-approved for paracetamol overdose (gold-standard antidote since 1976), A-tier psychiatric (OCD, trichotillomania, skin-picking), B-tier for addiction + cocaine craving + gambling. Crosses the BBB and replenishes brain glutathione better than direct GSH supplementation. Already in Dylan's V4 stack at 1200 mg/day — verdict is CONFIRMED-IN-USE. Mechanism stack is uniquely fit-for-purpose for an MMA athlete with daily subconcussive impact: it covers both oxidative stress (GSH precursor + direct ROS scavenger) and excitotoxicity (glutamate modulation via xCT/mGluR2/3) in one molecule. Continue at 1200 mg/day; consider 2400 mg/day on heavy sparring days as a post-impact rescue protocol.
▸ Mechanism of action
NAC is the N-acetylated form of L-cysteine. The acetyl group makes the molecule more stable, more bioavailable, and less prone to oxidation than free cysteine, which gets oxidized to insoluble cystine in air and stomach acid. After oral absorption (~6-10% systemic bioavailability — low but functionally adequate), NAC is deacetylated in the gut wall and liver, releasing L-cysteine, which then enters multiple downstream pathways:
Glutathione (GSH) synthesis — the main story. GSH is a tripeptide of glutamate-cysteine-glycine, synthesized in two ATP-dependent steps. Cysteine is the rate-limiting substrate in nearly all human tissue including brain, liver, lung. GSH is the body's master endogenous antioxidant — recycles vitamin C and vitamin E, neutralizes hydrogen peroxide via glutathione peroxidase (GPX), conjugates xenobiotics for excretion via glutathione-S-transferase (GST), and protects mitochondrial membrane lipids. Brain GSH declines with age and is depleted after TBI / subconcussive impact. NAC at 1200-2400 mg/day reliably raises plasma + tissue GSH in healthy and depleted populations.
Direct free-radical scavenger. The free sulfhydryl (-SH) on cysteine donates an electron to neutralize hydroxyl radicals, peroxynitrite, hypochlorous acid, and other reactive oxygen/nitrogen species. This is mechanism-independent of GSH synthesis and acts within minutes of dosing. Less potent per-mole than GSH itself but works in compartments where GSH can't reach.
Glutamate modulation via the cystine-glutamate antiporter (xCT / system Xc-). This is the brain-specific mechanism that distinguishes NAC from generic antioxidants. In glial cells, the xCT antiporter exchanges intracellular glutamate for extracellular cystine (oxidized cysteine dimer). NAC raises extracellular cystine → drives the antiporter → exports glutamate out of the synapse and into glia, where it's recycled. The exported glutamate stimulates mGluR2/3 presynaptic autoreceptors, which inhibit further synaptic glutamate release. Net effect: reduces tonic glutamate tone in cortex, striatum, and nucleus accumbens. This is the mechanism behind NAC's psychiatric effects — OCD, trichotillomania, addiction craving, schizophrenia adjunct.
Mucolytic — disulfide bond reduction. The free -SH cleaves disulfide bonds in mucin glycoproteins, breaking up thick mucus. This is the mechanism behind Mucomyst inhalation for cystic fibrosis and COPD. Not directly relevant to nootropic use, but explains the sulfur smell and explains why some users report runnier nasal mucus on NAC.
Heavy-metal chelation. Free thiol binds mercury, lead, arsenic, cadmium for excretion. Modest but real chelation activity at supplement doses.
Anti-inflammatory. Suppresses NF-κB activation; reduces IL-6, TNF-α, IL-1β; attenuates microglial activation in models of neuroinflammation. Convergent mechanism with curcumin and astaxanthin.
Paracetamol overdose antidote (the original FDA indication). Paracetamol (acetaminophen) at toxic doses is metabolized to NAPQI, a reactive electrophile that depletes hepatic GSH and causes liver necrosis. NAC restores GSH and directly scavenges NAPQI. Given IV (Acetadote) within 8-10 hours of overdose, mortality drops from ~30% to <5%. Gold-standard, on the WHO Essential Medicines List.
▸ Pharmacokinetics No data
▸Quality indicators4 checks
▸ What to expect Generic
- 1First doseFor stim-class powders: acute effect within 30-60 min.
- 2Week 1-2For volumizers (creatine, betaine): muscle fullness builds.
- 3Week 2-4Performance gains plateau into a new baseline.
- 4OngoingMaintenance dose continuous; cycle off only if specific indication.
▸ Side effects + safety
Common (>10% users):
- Sulfur / egg-like burp or breath — characteristic, dose-dependent, especially at >1200 mg empty stomach. Reduced by taking with food, splitting doses, or switching to enteric-coated form.
- Mild GI upset / nausea — usually at higher doses on empty stomach.
Less common (1-10%):
- Headache (mild)
- Diarrhea / loose stool (typically transient, dose-related)
- Skin rash (mild; rare in oral form, more common in IV)
Rare-serious (<1% but worth knowing):
- Anaphylactoid reaction (IV form mainly): Histamine-release reaction with rash, bronchospasm, hypotension during IV administration. Almost exclusively IV. Oral NAC has near-zero risk of this.
- Paradoxical bronchospasm (asthmatics, mainly inhaled form): Mucomyst inhalation can trigger acute bronchospasm in some asthmatics. Pre-treat with bronchodilator. Oral form has minimal asthma risk; some asthma patients report oral NAC reduces exacerbations (mucolytic + antioxidant).
- Hypotension at very high doses combined with nitroglycerin or other nitrate vasodilators: Real interaction (see drug interactions). Sub-clinical at supplement doses unless on nitrates.
- Theoretical bleeding risk with anticoagulants: NAC has mild antiplatelet activity in vitro. No bleeding events documented at supplement doses.
- Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis: Single case reports, extremely rare, IV form. Not a routine concern at oral supplement doses.
Specific watch periods: None standard. Asthmatics starting oral NAC for the first time should monitor for any breathing change in the first 1-2 weeks (very low probability of bronchospasm but worth noting).
Pregnancy / lactation: Used clinically in pregnancy (paracetamol overdose treatment in pregnant women is standard). FDA Pregnancy Category B. No teratogenicity signal. Lactation data limited; generally considered safe.
Long-term safety: Multiple human trials at 1200-2400 mg/day for 6-24 months show no chronic toxicity signal. COPD patients have used 600 mg BID for years. Maximum-tested daily dose in humans without serious adverse events: 8 g/day short-term. Practical chronic ceiling: 2400 mg/day for routine use; 4000 mg/day for short rescue periods.
Upper safe intake:
- No formal NOAEL / tolerable upper intake established by EFSA/FDA (it's a drug, not a nutrient).
- 2400 mg/day chronic = clinical OCD trial standard, well-tolerated.
- 4000 mg/day = used in TBI rescue protocol for ~4 days, well-tolerated short-term.
- 8000 mg/day = used in some IV paracetamol loading regimens, short-term clinical use only.
▸Interactions12 compounds
- glycineSynergisticGSH is gamma-Glu-Cys-Gly. Cysteine is rate-limiting in *most* tissues, but glycine becomes co-limiting in older adults and during chronic illness (Sekhar 201…
- curcumin (V4 — Doctor's Best Curcumin Phytosome 500 mg)SynergisticBoth anti-inflammatory, both Nrf2 activators, both hit microglial NF-κB. Convergent on neuroinflammation. Stack in same morning dose. Mechanism overlap is pa…
- astaxanthin (V5 add)SynergisticAstaxanthin protects mitochondrial + neuronal membranes from lipid peroxidation; NAC replenishes the GSH pool that recycles oxidized vitamin E and supports g…
- omega-3 / DHA (V4 — Carlson Super DHA Gems 2 g)SynergisticDHA is the most peroxidation-vulnerable fatty acid in brain membranes. NAC + GSH protects DHA from oxidation; astaxanthin also covers this. Triad mechanism —…
- vitamin C (V4 — CGN 500 mg)SynergisticVitamin C regenerates oxidized vitamin E; NAC regenerates GSH which regenerates vitamin C. Network antioxidant cycle. Already in V4 — no change needed.
- magnesium (V4 — Magtein + Mg Glycinate)SynergisticNMDA receptor magnesium block + NAC's xCT-mediated glutamate reduction = layered protection against glutamate excitotoxicity. Particularly relevant for post-…
- agmatineSynergisticDirect NMDA antagonist + iNOS inhibitor + neuroprotective in TBI models. Mechanistic overlap with NAC's glutamate axis but different molecular target. Both d…
- alcohol pre/post protocol (anecdotal but mechanistic)SynergisticAlcohol metabolism via ADH/ALDH depletes hepatic GSH and produces acetaldehyde. NAC 600-1200 mg pre-drinking + 1200 mg morning-after restores GSH and helps c…
- Nitroglycerin / organic nitrates (isosorbide mononitrate/dinitrate)AvoidNAC potentiates nitrate-induced vasodilation, can cause severe hypotension + headache. Documented interaction. Not relevant to Dylan but absolute contraindic…
- Activated charcoal (acute poisoning context)AvoidNAC binds activated charcoal, reducing absorption. In paracetamol overdose, charcoal and NAC are spaced apart by hours. Not a daily-stack concern.
- Carbamazepine, antipsychotics, antiepileptics — theoreticalAvoidNAC can shift glutamate tone; in patients on glutamate-modulating drugs, monitor. No documented bad interactions but worth flagging for psych populations.
- Anticoagulants (warfarin, DOACs) at high NAC dosesAvoidTheoretical antiplatelet potentiation. Sub-clinical at 1200 mg/day. Not relevant to Dylan.
▸References33 sources
Acetadote (IV NAC) FDA label
official label for IV NAC paracetamol overdose
Prescott et al. 1977 — IV NAC in paracetamol overdose: original landmark study
1977foundational efficacy data
Smilkstein et al. 1988 — Efficacy of oral NAC in 11,195 paracetamol overdose patients
1988large prospective registry confirming oral efficacy
Grant et al. 2009 — N-Acetylcysteine, a glutamate modulator, in the treatment of trichotillomania (Arch Gen Psychiatry)
2009landmark trichotillomania RCT
Costa et al. 2017 — NAC for OCD: 8-week double-blind RCT
2017OCD adjunct
2022 Cochrane / meta-analysis on NAC in OCD spectrum disorders
2022meta-analytic confirmation
Lee et al. 2022 — NAC in trichotillomania and skin-picking: meta-analysis
2022BFRB meta-analysis
Hoffer et al. 2013 — Amelioration of acute sequelae of blast-induced mild TBI by N-acetyl cysteine: military RCT
2013the closest direct human translation to Dylan's use case
Eakin et al. 2014 — NAC in animal models of repetitive mild TBI
2014mechanism replication in animal model
2024 Frontiers in Neurology review of NAC in TBI
2024recent comprehensive review
Berk et al. 2008 — NAC adjunct in schizophrenia: 6-month RCT
2008landmark schizophrenia trial
Berk et al. 2014 — NAC adjunct in bipolar depression
2014bipolar adjunct
LaRowe et al. 2013 — NAC for cocaine dependence: large RCT
2013cocaine craving reduction
Gray et al. 2017 — NAC for cannabis cessation: large RCT
2017cannabis cessation
Grant et al. 2014 — NAC for pathological gambling: RCT
2014gambling craving
Fernandes et al. 2019 — NAC in depression meta-analysis
2019depression adjunct meta-analysis
Aldini et al. 2018 — NAC: an old drug with new pharmacological insights, Free Rad Biol Med
2018comprehensive mechanism review
Berk et al. 2013 — The promise of NAC in neuropsychiatry
2013clinical psychiatry mechanism review
Mocelin et al. 2019 — NAC behavioral effects via glutamate cysteine antiporter (xCT)
2019xCT mechanism
2024 Frontiers in Pharmacology — NAC mechanism in neuroprotection
2024recent mechanism review
Kumar et al. 2021 — GlyNAC in older adults: 24-week trial
2021older-adult GlyNAC trial (Baylor)
Sekhar et al. 2011 — Glycine and cysteine co-limit GSH synthesis in elderly
2011GlyNAC rationale paper
2025 Aging Cell — GlyNAC mitochondrial function in older adults
2025recent confirmation
FDA 2022 Final Guidance on NAC enforcement discretion
2022official FDA enforcement-discretion guidance
FDA 2020 warning letters on NAC supplements
2020original 2020 warning letters
CRN 2022 statement on FDA NAC guidance
2022industry trade group response
Holdiness 1991 — Clinical pharmacokinetics of NAC
1991pharmacokinetic foundation
Atkuri et al. 2007 — NAC: a safe antidote for cysteine/glutathione deficiency
2007safety review
Sansone & Sansone 2011 — Getting a Knack for NAC: clinical psychiatry safety review
2011clinical safety summary
Swanson NAC 600 mg, iHerb
Dylan's V4 supplier
NOW Foods NAC 600 mg, iHerb
premium alternative
Jarrow NAC Sustain 600 mg, iHerb
sustained-release option
Nootropics Depot NAC
third-party tested